- Home
- / Poseida Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Poseida Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$64.7 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 03, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|
| Revenue | 31.2M | 130.5M | 64.7M | |
| General and administrative expense | 23.0M | 35.9M | 37.5M | 37.4M |
| Operating expense total | 126.5M | 172.6M | 190.4M | |
| EBIT | (126.5M) | (141.4M) | (59.9M) | (129.5M) |
| EBIT margin, % | -452.7% | -45.9% | ||
| Interest expense | 3.5M | 3.4M | 6.4M | 8.7M |
| Pre tax profit | (129.8M) | (125.0M) | (63.5M) | (123.3M) |
| Income tax expense | 544.0K | 100.0K | ||
| Net Income | (129.8M) | (125.0M) | (64.0M) | (123.4M) |
| EPS | (0.9) | (1.0) |